RedHill Biopharma (RDHL) Interest Expenses (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Interest Expenses data on file, last reported at $1.9 million in Q2 2023.

• Interest Expenses for Q2 2023 came in at $1.9 million, down 54.3% year-over-year; the trailing twelve-month figure through Dec 2024 was $1.9 million (down 60.11% YoY), and the FY2025 annual result was $1.5 million, down 3.7% from the prior year.
• Interest Expenses grew to $1.9 million in Q2 2023 per RDHL's latest filing, from $421000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $28.6 million in Q3 2022 and troughed at $74000.0 in Q2 2019.
• A 5-year average of $4.0 million and a median of $3.7 million in 2020 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2019 and 2020: Interest Expenses plunged 95.69% in 2019, then surged 4839.19% in 2020.
• A 5-year view of Interest Expenses shows it stood at $187000.0 in 2019, then surged by 2335.29% to $4.6 million in 2020, then retreated by 19.06% to $3.7 million in 2021, then slumped by 32.69% to $2.5 million in 2022, then decreased by 22.37% to $1.9 million in 2023.
• Business Quant data shows RDHL's Interest Expenses at $1.9 million in Q2 2023, $421000.0 in Q1 2023, and $2.5 million in Q4 2022.